Please ensure Javascript is enabled for purposes of website accessibility

Moderna Prepares to Manufacture a Billion Doses of Coronavirus Vaccine

By Jim Crumly – May 1, 2020 at 1:03PM

You’re reading a free article with opinions that may differ from The Motley Fool’s Premium Investing Services. Become a Motley Fool member today to get instant access to our top analyst recommendations, in-depth research, investing resources, and more. Learn More

A deal with Swiss drugmaker Lonza expands manufacturing capacity tenfold.

Biotech Moderna (MRNA 3.26%) announced an agreement with Swiss drugmaker Lonza Group (LZAGY 3.17%) to manufacture up to a billion doses per year of mRNA-1273, Moderna's vaccine candidate for the novel coronavirus.

The two companies initially plan to establish manufacturing capabilities at Lonza's facilities in the U.S. and Switzerland to make the vaccine at both locations, with additional production suites to be established across Lonza's worldwide facilities under the 10-year agreement. The companies expect to produce the first batches of mRNA-1273 at Lonza's U.S. facility in July 2020. A portion of the funding for the manufacturing operations in the U.S. will come from Moderna's contract with Biomedical Advanced Research and Development Authority (BARDA), part of the U.S. Department of Health and Human Services.

Bottles of novel coronavirus vaccine.

Image source: Getty Images.

Moderna, which has a platform based on messenger RNA (mRNA) that can develop new vaccine candidates in days, is currently conducting phase 1 trials of mRNA-1273 and has submitted an application to the U.S. Food and Drug Administration (FDA) to initiate phase 2 testing this fall. The company also has the capability to manufacture the vaccine, but the deal with Lonza will increase its capacity by a factor of 10.

Shares of Moderna, already up 135% this year, initially rose another 6% on the news, and the American depositary receipts (ADRs) of Lonza were up 5% in Friday morning trading.

Jim Crumly has no position in any of the stocks mentioned. The Motley Fool has no position in any of the stocks mentioned. The Motley Fool has a disclosure policy.

Invest Smarter with The Motley Fool

Join Over 1 Million Premium Members Receiving…

  • New Stock Picks Each Month
  • Detailed Analysis of Companies
  • Model Portfolios
  • Live Streaming During Market Hours
  • And Much More
Get Started Now

Stocks Mentioned

Moderna, Inc. Stock Quote
Moderna, Inc.
MRNA
$123.59 (3.26%) $3.90
Lonza Group Ltd Stock Quote
Lonza Group Ltd
LZAGY
$45.57 (3.17%) $1.40

*Average returns of all recommendations since inception. Cost basis and return based on previous market day close.

Related Articles

Motley Fool Returns

Motley Fool Stock Advisor

Market-beating stocks from our award-winning analyst team.

Stock Advisor Returns
327%
 
S&P 500 Returns
105%

Calculated by average return of all stock recommendations since inception of the Stock Advisor service in February of 2002. Returns as of 09/27/2022.

Discounted offers are only available to new members. Stock Advisor list price is $199 per year.

Premium Investing Services

Invest better with The Motley Fool. Get stock recommendations, portfolio guidance, and more from The Motley Fool's premium services.